ArticleGenome medicine2026
DposFinder: an interpretable transformer model for predicting phage-derived polysaccharide depolymerases and their host capsular serotypes.
Article in Genome medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPolysaccharide depolymerases derived from phages play a pivotal role in the degradation of bacterial surface polysaccharides, offering a promising strategy to address antibiotic-resistant bacterial strains. However, the identification of these enzymes along with their associated host capsular serotypes poses significant challenges. This study introduces DposFinder, a transformer-based deep learning framework designed to predict depolymerases alongside their host capsular serotypes, thereby facilitating large-scale discovery and application of these enzymes.
methodsWe developed DposFinder as an interpretable model based on transformer architecture, utilizing the pre-trained protein language model ESM-2. The model’s attention mechanism was harnessed to pinpoint β-helix domains of depolymerases and predict their corresponding host capsular serotypes. DposFinder’s performance was evaluated through extensive benchmarking and experimental validation involving sequenced phages of Klebsiella pneumoniae.
resultsDposFinder achieved state-of-the-art performance, with an area under the ROC curve (AUC) of 0.991 on an independent test dataset, outperforming existing depolymerase prediction tools. Experimental validation confirmed the predictions of six novel depolymerases, which exhibited less than 50% sequence identity with known depolymerases. Furthermore, DposFinder successfully predicted the host capsular serotypes for the identified depolymerases. The utility of the model was further demonstrated through improved plasmid electroporation efficiency in hypermucoviscous K. pneumoniae isolates and the facilitation of host-serotype-labeled phage library construction. A publicly accessible database was also established, containing over 100,000 putative depolymerases derived from more than 440,000 phage genomic sequences.
conclusionsDposFinder is a novel framework capable of predicting both depolymerases and their associated host capsular serotypes. Its interpretative capabilities and scalability render it a powerful tool for expediting the discovery and application of phage-derived depolymerases in biomedical research and phage therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.